Skip to main content
Erschienen in: Pathology & Oncology Research 3/2019

09.11.2018 | Original Article

MicroRNA Expression in Focal Nodular Hyperplasia in Comparison with Cirrhosis and Hepatocellular Carcinoma

verfasst von: Gábor Lendvai, Tímea Szekerczés, Benedek Gyöngyösi, Krisztina Schlachter, Endre Kontsek, Adrián Pesti, Attila Patonai, Klára Werling, Ilona Kovalszky, Zsuzsa Schaff, András Kiss

Erschienen in: Pathology & Oncology Research | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

The liver disease focal nodular hyperplasia (FNH) has several histological features that resemble hepatic cirrhosis. Since cirrhosis may develop further into hepatocellular carcinoma (HCC) contrary to FNH, the aim of the present study was to identify microRNAs (miRNA), which, by their altered expression levels, may be associated with the benign, tumor-like nature of FNH. Altogether 106 surgically removed formalin-fixed paraffin-embedded liver samples were selected, including 22 FNH, 45 cirrhosis, 24 HCC and 15 normal liver tissues. Etiology of the cases of cirrhosis and HCC includes hepatitis C and alcoholism and the HCC cases developed in cirrhotic livers. Relative expression levels of 14 miRNAs were determined using TaqMan MicroRNA Assays. In comparison to normal liver, the levels of miR-34a and miR-224 were elevated not only in FNH but also in cirrhosis and HCC, while the expression of miR-17-5p, miR-18a and miR-210 was decreased in FNH. Further, the levels of miR-21 and miR-222 were increased in cirrhosis and HCC but were decreased in FNH and the expression of miR-17-5p, miR-18a, miR-195 and miR-210 was decreased in FNH as compared with cirrhosis and/or HCC. In conclusion, the elevation of miR-34a and miR-224 may be associated with both benign and malignant proliferative processes, nevertheless the increased expression of oncomiRs miR-21 and miR-222 in cirrhosis and HCC but not in FNH may be related to malignant processes of the liver. The decreased levels of miR-18a, miR-195 and miR-210 may further differentiate FNH from cirrhosis, reflecting the different pathogenesis of these two entities contrary to some histologically similar features.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Chen SL, Zheng MH, Shi KQ, Yang T, Chen YP (2013) A new strategy for treatment of liver fibrosis: letting MicroRNAs do the job. BioDrugs 27(1):25–34CrossRef Chen SL, Zheng MH, Shi KQ, Yang T, Chen YP (2013) A new strategy for treatment of liver fibrosis: letting MicroRNAs do the job. BioDrugs 27(1):25–34CrossRef
2.
Zurück zum Zitat Mormone E, George J, Nieto N (2011) Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chem Biol Interact 193(3):225–231CrossRef Mormone E, George J, Nieto N (2011) Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chem Biol Interact 193(3):225–231CrossRef
3.
Zurück zum Zitat Roncalli M, Sciarra A, Tommaso LD (2016) Benign hepatocellular nodules of healthy liver: focal nodular hyperplasia and hepatocellular adenoma. Clin Mol Hepatol 22(2):199–211CrossRef Roncalli M, Sciarra A, Tommaso LD (2016) Benign hepatocellular nodules of healthy liver: focal nodular hyperplasia and hepatocellular adenoma. Clin Mol Hepatol 22(2):199–211CrossRef
4.
Zurück zum Zitat Balabaud C, Al-Rabih WR, Chen PJ, Evason K, Ferrell L, Hernandez-Prera JC, Huang SF, Longerich T, Park YN, Quaglia A, Schirmacher P, Sempoux C, Thung SN, Torbenson M, Wee A, Yeh MM, Yeh SH, Le Bail B, Zucman-Rossi J, Bioulac-Sage P (2013) Focal nodular hyperplasia and hepatocellular adenoma around the world viewed through the scope of the Immunopathological classification. Int J Hepatol 2013:268625 Balabaud C, Al-Rabih WR, Chen PJ, Evason K, Ferrell L, Hernandez-Prera JC, Huang SF, Longerich T, Park YN, Quaglia A, Schirmacher P, Sempoux C, Thung SN, Torbenson M, Wee A, Yeh MM, Yeh SH, Le Bail B, Zucman-Rossi J, Bioulac-Sage P (2013) Focal nodular hyperplasia and hepatocellular adenoma around the world viewed through the scope of the Immunopathological classification. Int J Hepatol 2013:268625
5.
Zurück zum Zitat Kondo F, Fukusato T, Kudo M (2014) Pathological diagnosis of benign hepatocellular nodular lesions based on the new World Health Organization classification. Oncology 87(Suppl 1):37–49CrossRef Kondo F, Fukusato T, Kudo M (2014) Pathological diagnosis of benign hepatocellular nodular lesions based on the new World Health Organization classification. Oncology 87(Suppl 1):37–49CrossRef
6.
Zurück zum Zitat Sempoux C, Balabaud C, Bioulac-Sage P (2014) Pictures of focal nodular hyperplasia and hepatocellular adenomas. World J Hepatol 6(8):580–595CrossRef Sempoux C, Balabaud C, Bioulac-Sage P (2014) Pictures of focal nodular hyperplasia and hepatocellular adenomas. World J Hepatol 6(8):580–595CrossRef
7.
Zurück zum Zitat Venturi A, Piscaglia F, Vidili G, Flori S, Righini R, Golfieri R, Bolondi L (2007) Diagnosis and management of hepatic focal nodular hyperplasia. J Ultrasound 10(3):116–127CrossRef Venturi A, Piscaglia F, Vidili G, Flori S, Righini R, Golfieri R, Bolondi L (2007) Diagnosis and management of hepatic focal nodular hyperplasia. J Ultrasound 10(3):116–127CrossRef
8.
Zurück zum Zitat Nahm CB, Ng K, Lockie P, Samra JS, Hugh TJ (2011) Focal nodular hyperplasia--a review of myths and truths. J Gastrointest Surg 15(12):2275–2283CrossRef Nahm CB, Ng K, Lockie P, Samra JS, Hugh TJ (2011) Focal nodular hyperplasia--a review of myths and truths. J Gastrointest Surg 15(12):2275–2283CrossRef
9.
Zurück zum Zitat Sohrabpour AA, Mohamadnejad M, Malekzadeh R (2012) Review article: the reversibility of cirrhosis. Aliment Pharmacol Ther 36(9):824–832CrossRef Sohrabpour AA, Mohamadnejad M, Malekzadeh R (2012) Review article: the reversibility of cirrhosis. Aliment Pharmacol Ther 36(9):824–832CrossRef
10.
Zurück zum Zitat Liou IW (2014) Management of end-stage liver disease. Med Clin North Am 98(1):119–152CrossRef Liou IW (2014) Management of end-stage liver disease. Med Clin North Am 98(1):119–152CrossRef
11.
Zurück zum Zitat Murakami Y, Kawada N (2017) MicroRNAs in hepatic pathophysiology. Hepatol Res 47(1):60–69CrossRef Murakami Y, Kawada N (2017) MicroRNAs in hepatic pathophysiology. Hepatol Res 47(1):60–69CrossRef
12.
Zurück zum Zitat Bandiera S, Pfeffer S, Baumert TF, Zeisel MB (2015) miR-122--a key factor and therapeutic target in liver disease. J Hepatol 62(2):448–457CrossRef Bandiera S, Pfeffer S, Baumert TF, Zeisel MB (2015) miR-122--a key factor and therapeutic target in liver disease. J Hepatol 62(2):448–457CrossRef
13.
Zurück zum Zitat Hu J, Xu Y, Hao J, Wang S, Li C, Meng S (2012) MiR-122 in hepatic function and liver diseases. Protein Cell 3(5):364–371CrossRef Hu J, Xu Y, Hao J, Wang S, Li C, Meng S (2012) MiR-122 in hepatic function and liver diseases. Protein Cell 3(5):364–371CrossRef
14.
Zurück zum Zitat Lee CH, Kim JH, Lee SW (2014) The role of microRNAs in hepatitis C virus replication and related liver diseases. J Microbiol 52(6):445–451CrossRef Lee CH, Kim JH, Lee SW (2014) The role of microRNAs in hepatitis C virus replication and related liver diseases. J Microbiol 52(6):445–451CrossRef
15.
Zurück zum Zitat Huan L, Liang LH, He XH (2016) Role of microRNAs in inflammation-associated liver cancer. Cancer Biol Med 13(4):407–425CrossRef Huan L, Liang LH, He XH (2016) Role of microRNAs in inflammation-associated liver cancer. Cancer Biol Med 13(4):407–425CrossRef
16.
Zurück zum Zitat Lendvai G, Jarmay K, Karacsony G, Halasz T, Kovalszky I, Baghy K, Wittmann T, Schaff Z, Kiss A (2014) Elevated miR-33a and miR-224 in steatotic chronic hepatitis C liver biopsies. World J Gastroenterol 20(41):15343–15350CrossRef Lendvai G, Jarmay K, Karacsony G, Halasz T, Kovalszky I, Baghy K, Wittmann T, Schaff Z, Kiss A (2014) Elevated miR-33a and miR-224 in steatotic chronic hepatitis C liver biopsies. World J Gastroenterol 20(41):15343–15350CrossRef
17.
Zurück zum Zitat Gyugos M, Lendvai G, Kenessey I, Schlachter K, Halasz J, Nagy P, Garami M, Jakab Z, Schaff Z, Kiss A (2014) MicroRNA expression might predict prognosis of epithelial hepatoblastoma. Virchows Arch 464(4):419–427CrossRef Gyugos M, Lendvai G, Kenessey I, Schlachter K, Halasz J, Nagy P, Garami M, Jakab Z, Schaff Z, Kiss A (2014) MicroRNA expression might predict prognosis of epithelial hepatoblastoma. Virchows Arch 464(4):419–427CrossRef
18.
Zurück zum Zitat Szabo G, Bala S (2013) MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol 10(9):542–552CrossRef Szabo G, Bala S (2013) MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol 10(9):542–552CrossRef
19.
Zurück zum Zitat Halasz T, Horvath G, Par G, Werling K, Kiss A, Schaff Z, Lendvai G (2015) miR-122 negatively correlates with liver fibrosis as detected by histology and FibroScan. World J Gastroenterol 21(25):7814–7823CrossRef Halasz T, Horvath G, Par G, Werling K, Kiss A, Schaff Z, Lendvai G (2015) miR-122 negatively correlates with liver fibrosis as detected by histology and FibroScan. World J Gastroenterol 21(25):7814–7823CrossRef
20.
Zurück zum Zitat Doleshal M, Magotra AA, Choudhury B, Cannon BD, Labourier E, Szafranska AE (2008) Evaluation and validation of total RNA extraction methods for microRNA expression analyses in formalin-fixed, paraffin-embedded tissues. J Mol Diagn 10(3):203–211CrossRef Doleshal M, Magotra AA, Choudhury B, Cannon BD, Labourier E, Szafranska AE (2008) Evaluation and validation of total RNA extraction methods for microRNA expression analyses in formalin-fixed, paraffin-embedded tissues. J Mol Diagn 10(3):203–211CrossRef
21.
Zurück zum Zitat Borel F, Konstantinova P, Jansen PL (2012) Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol 56(6):1371–1383CrossRef Borel F, Konstantinova P, Jansen PL (2012) Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol 56(6):1371–1383CrossRef
22.
Zurück zum Zitat Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S, Zucman-Rossi J (2008) MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 47(6):1955–1963CrossRef Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S, Zucman-Rossi J (2008) MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 47(6):1955–1963CrossRef
23.
Zurück zum Zitat Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K (2006) Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 25(17):2537–2545CrossRef Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K (2006) Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 25(17):2537–2545CrossRef
24.
Zurück zum Zitat Andersen CL, Jensen JL, Orntoft TF (2004) Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 64(15):5245–5250CrossRef Andersen CL, Jensen JL, Orntoft TF (2004) Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 64(15):5245–5250CrossRef
25.
Zurück zum Zitat Bioulac-Sage P, Balabaud C, Bedossa P, Scoazec JY, Chiche L, Dhillon AP, Ferrell L, Paradis V, Roskams T, Vilgrain V, Wanless IR, Zucman-Rossi J (2007) Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update. J Hepatol 46(3):521–527CrossRef Bioulac-Sage P, Balabaud C, Bedossa P, Scoazec JY, Chiche L, Dhillon AP, Ferrell L, Paradis V, Roskams T, Vilgrain V, Wanless IR, Zucman-Rossi J (2007) Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update. J Hepatol 46(3):521–527CrossRef
26.
Zurück zum Zitat Maillette de Buy Wenniger L, Terpstra V, Beuers U (2010) Focal nodular hyperplasia and hepatic adenoma: epidemiology and pathology. Dig Surg 27(1):24–31CrossRef Maillette de Buy Wenniger L, Terpstra V, Beuers U (2010) Focal nodular hyperplasia and hepatic adenoma: epidemiology and pathology. Dig Surg 27(1):24–31CrossRef
27.
Zurück zum Zitat Pinzani M (2015) Pathophysiology of liver fibrosis. Dig Dis 33(4):492–497CrossRef Pinzani M (2015) Pathophysiology of liver fibrosis. Dig Dis 33(4):492–497CrossRef
28.
Zurück zum Zitat He Y, Huang C, Zhang SP, Sun X, Long XR, Li J (2012) The potential of microRNAs in liver fibrosis. Cell Signal 24(12):2268–2272CrossRef He Y, Huang C, Zhang SP, Sun X, Long XR, Li J (2012) The potential of microRNAs in liver fibrosis. Cell Signal 24(12):2268–2272CrossRef
29.
Zurück zum Zitat Roderburg C, Luedde T (2014) Circulating microRNAs as markers of liver inflammation, fibrosis and cancer. J Hepatol 61(6):1434–1437CrossRef Roderburg C, Luedde T (2014) Circulating microRNAs as markers of liver inflammation, fibrosis and cancer. J Hepatol 61(6):1434–1437CrossRef
30.
Zurück zum Zitat Tian XF, Ji FJ, Zang HL, Cao H (2016) Activation of the miR-34a/SIRT1/p53 signaling pathway contributes to the Progress of liver fibrosis via inducing apoptosis in hepatocytes but not in HSCs. PLoS One 11(7):e0158657CrossRef Tian XF, Ji FJ, Zang HL, Cao H (2016) Activation of the miR-34a/SIRT1/p53 signaling pathway contributes to the Progress of liver fibrosis via inducing apoptosis in hepatocytes but not in HSCs. PLoS One 11(7):e0158657CrossRef
31.
Zurück zum Zitat Ding J, Li M, Wan X, Jin X, Chen S, Yu C, Li Y (2015) Effect of miR-34a in regulating steatosis by targeting PPARalpha expression in nonalcoholic fatty liver disease. Sci Rep 5:13729CrossRef Ding J, Li M, Wan X, Jin X, Chen S, Yu C, Li Y (2015) Effect of miR-34a in regulating steatosis by targeting PPARalpha expression in nonalcoholic fatty liver disease. Sci Rep 5:13729CrossRef
32.
Zurück zum Zitat Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, Mazzaferro V, Lowe SW, Croce CM, Dejean A (2010) miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A 107(1):264–269CrossRef Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, Mazzaferro V, Lowe SW, Croce CM, Dejean A (2010) miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A 107(1):264–269CrossRef
33.
Zurück zum Zitat Han Y, Meng F, Venter J, Wu N, Wan Y, Standeford H, Francis H, Meininger C, Greene J Jr, Trzeciakowski JP, Ehrlich L, Glaser S, Alpini G (2016) miR-34a-dependent overexpression of Per1 decreases cholangiocarcinoma growth. J Hepatol 64(6):1295–1304CrossRef Han Y, Meng F, Venter J, Wu N, Wan Y, Standeford H, Francis H, Meininger C, Greene J Jr, Trzeciakowski JP, Ehrlich L, Glaser S, Alpini G (2016) miR-34a-dependent overexpression of Per1 decreases cholangiocarcinoma growth. J Hepatol 64(6):1295–1304CrossRef
34.
Zurück zum Zitat Yan G, Li B, Xin X, Xu M, Ji G, Yu H (2015) MicroRNA-34a promotes hepatic stellate cell activation via targeting ACSL1. Med Sci Monit 21:3008–3015CrossRef Yan G, Li B, Xin X, Xu M, Ji G, Yu H (2015) MicroRNA-34a promotes hepatic stellate cell activation via targeting ACSL1. Med Sci Monit 21:3008–3015CrossRef
35.
Zurück zum Zitat Sato Y, Harada K, Ikeda H, Fijii T, Sasaki M, Zen Y, Nakanuma Y (2009) Hepatic stellate cells are activated around central scars of focal nodular hyperplasia of the liver--a potential mechanism of central scar formation. Hum Pathol 40(2):181–188CrossRef Sato Y, Harada K, Ikeda H, Fijii T, Sasaki M, Zen Y, Nakanuma Y (2009) Hepatic stellate cells are activated around central scars of focal nodular hyperplasia of the liver--a potential mechanism of central scar formation. Hum Pathol 40(2):181–188CrossRef
36.
Zurück zum Zitat Cheng J, Zhou L, Xie QF, Xie HY, Wei XY, Gao F, Xing CY, Xu X, Li LJ, Zheng SS (2010) The impact of miR-34a on protein output in hepatocellular carcinoma HepG2 cells. Proteomics 10(8):1557–1572CrossRef Cheng J, Zhou L, Xie QF, Xie HY, Wei XY, Gao F, Xing CY, Xu X, Li LJ, Zheng SS (2010) The impact of miR-34a on protein output in hepatocellular carcinoma HepG2 cells. Proteomics 10(8):1557–1572CrossRef
37.
Zurück zum Zitat Ma D, Tao X, Gao F, Fan C, Wu D (2012) miR-224 functions as an onco-miRNA in hepatocellular carcinoma cells by activating AKT signaling. Oncol Lett 4(3):483–488CrossRef Ma D, Tao X, Gao F, Fan C, Wu D (2012) miR-224 functions as an onco-miRNA in hepatocellular carcinoma cells by activating AKT signaling. Oncol Lett 4(3):483–488CrossRef
38.
Zurück zum Zitat Wang Y, Ren J, Gao Y, Ma JZ, Toh HC, Chow P, Chung AY, Ooi LL, Lee CG (2013) MicroRNA-224 targets SMAD family member 4 to promote cell proliferation and negatively influence patient survival. PLoS One 8(7):e68744CrossRef Wang Y, Ren J, Gao Y, Ma JZ, Toh HC, Chow P, Chung AY, Ooi LL, Lee CG (2013) MicroRNA-224 targets SMAD family member 4 to promote cell proliferation and negatively influence patient survival. PLoS One 8(7):e68744CrossRef
39.
Zurück zum Zitat Li Q, Ding C, Chen C, Zhang Z, Xiao H, Xie F, Lei L, Chen Y, Mao B, Jiang M, Li J, Wang D, Wang G (2014) miR-224 promotion of cell migration and invasion by targeting Homeobox D 10 gene in human hepatocellular carcinoma. J Gastroenterol Hepatol 29(4):835–842CrossRef Li Q, Ding C, Chen C, Zhang Z, Xiao H, Xie F, Lei L, Chen Y, Mao B, Jiang M, Li J, Wang D, Wang G (2014) miR-224 promotion of cell migration and invasion by targeting Homeobox D 10 gene in human hepatocellular carcinoma. J Gastroenterol Hepatol 29(4):835–842CrossRef
40.
Zurück zum Zitat Scisciani C, Vossio S, Guerrieri F, Schinzari V, De Iaco R, de Meo D’Onorio P, Cervello M, Montalto G, Pollicino T, Raimondo G, Levrero M, Pediconi N (2012) Transcriptional regulation of miR-224 upregulated in human HCCs by NFkappaB inflammatory pathways. J Hepatol 56(4):855–861CrossRef Scisciani C, Vossio S, Guerrieri F, Schinzari V, De Iaco R, de Meo D’Onorio P, Cervello M, Montalto G, Pollicino T, Raimondo G, Levrero M, Pediconi N (2012) Transcriptional regulation of miR-224 upregulated in human HCCs by NFkappaB inflammatory pathways. J Hepatol 56(4):855–861CrossRef
41.
Zurück zum Zitat Gyongyosi B, Vegh E, Jaray B, Szekely E, Fassan M, Bodoky G, Schaff Z, Kiss A (2014) Pretreatment MicroRNA level and outcome in Sorafenib-treated hepatocellular carcinoma. J Histochem Cytochem 62(8):547–555CrossRef Gyongyosi B, Vegh E, Jaray B, Szekely E, Fassan M, Bodoky G, Schaff Z, Kiss A (2014) Pretreatment MicroRNA level and outcome in Sorafenib-treated hepatocellular carcinoma. J Histochem Cytochem 62(8):547–555CrossRef
42.
Zurück zum Zitat Iorio MV, Croce CM (2012) microRNA involvement in human cancer. Carcinogenesis 33(6):1126–1133CrossRef Iorio MV, Croce CM (2012) microRNA involvement in human cancer. Carcinogenesis 33(6):1126–1133CrossRef
43.
Zurück zum Zitat Wong QW, Ching AK, Chan AW, Choy KW, To KF, Lai PB, Wong N (2010) MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin Cancer Res 16(3):867–875CrossRef Wong QW, Ching AK, Chan AW, Choy KW, To KF, Lai PB, Wong N (2010) MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin Cancer Res 16(3):867–875CrossRef
44.
Zurück zum Zitat He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X (2015) MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway. Oncotarget 6(30):28867–28881PubMedPubMedCentral He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X (2015) MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway. Oncotarget 6(30):28867–28881PubMedPubMedCentral
45.
Zurück zum Zitat Bao L, Yan Y, Xu C, Ji W, Shen S, Xu G, Zeng Y, Sun B, Qian H, Chen L, Wu M, Su C, Chen J (2013) MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways. Cancer Lett 337(2):226–236CrossRef Bao L, Yan Y, Xu C, Ji W, Shen S, Xu G, Zeng Y, Sun B, Qian H, Chen L, Wu M, Su C, Chen J (2013) MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways. Cancer Lett 337(2):226–236CrossRef
46.
Zurück zum Zitat Yang YF, Wang F, Xiao JJ, Song Y, Zhao YY, Cao Y, Bei YH, Yang CQ (2014) MiR-222 overexpression promotes proliferation of human hepatocellular carcinoma HepG2 cells by downregulating p27. Int J Clin Exp Med 7(4):893–902PubMedPubMedCentral Yang YF, Wang F, Xiao JJ, Song Y, Zhao YY, Cao Y, Bei YH, Yang CQ (2014) MiR-222 overexpression promotes proliferation of human hepatocellular carcinoma HepG2 cells by downregulating p27. Int J Clin Exp Med 7(4):893–902PubMedPubMedCentral
47.
Zurück zum Zitat Melnik BC (2015) MiR-21: an environmental driver of malignant melanoma? J Transl Med 13:202CrossRef Melnik BC (2015) MiR-21: an environmental driver of malignant melanoma? J Transl Med 13:202CrossRef
48.
Zurück zum Zitat Tili E, Michaille JJ, Croce CM (2013) MicroRNAs play a central role in molecular dysfunctions linking inflammation with cancer. Immunol Rev 253(1):167–184CrossRef Tili E, Michaille JJ, Croce CM (2013) MicroRNAs play a central role in molecular dysfunctions linking inflammation with cancer. Immunol Rev 253(1):167–184CrossRef
49.
Zurück zum Zitat Ogawa T, Enomoto M, Fujii H, Sekiya Y, Yoshizato K, Ikeda K, Kawada N (2012) MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. Gut 61(11):1600–1609CrossRef Ogawa T, Enomoto M, Fujii H, Sekiya Y, Yoshizato K, Ikeda K, Kawada N (2012) MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. Gut 61(11):1600–1609CrossRef
50.
Zurück zum Zitat Kim Y, Jho EH (2017) Deubiquitinase YOD1: the potent activator of YAP in hepatomegaly and liver cancer. BMB Rep 50(6):281–282CrossRef Kim Y, Jho EH (2017) Deubiquitinase YOD1: the potent activator of YAP in hepatomegaly and liver cancer. BMB Rep 50(6):281–282CrossRef
51.
Zurück zum Zitat Patel SH, Camargo FD, Yimlamai D (2017) Hippo signaling in the liver regulates organ size, cell fate, and Carcinogenesis. Gastroenterology 152(3):533–545CrossRef Patel SH, Camargo FD, Yimlamai D (2017) Hippo signaling in the liver regulates organ size, cell fate, and Carcinogenesis. Gastroenterology 152(3):533–545CrossRef
52.
Zurück zum Zitat Cloonan N, Brown MK, Steptoe AL, Wani S, Chan WL, Forrest AR, Kolle G, Gabrielli B, Grimmond SM (2008) The miR-17-5p microRNA is a key regulator of the G1/S phase cell cycle transition. Genome Biol 9(8):R127CrossRef Cloonan N, Brown MK, Steptoe AL, Wani S, Chan WL, Forrest AR, Kolle G, Gabrielli B, Grimmond SM (2008) The miR-17-5p microRNA is a key regulator of the G1/S phase cell cycle transition. Genome Biol 9(8):R127CrossRef
53.
Zurück zum Zitat Liu L, Cai X, Liu E, Tian X, Tian C (2017) MicroRNA-18a promotes proliferation and metastasis in hepatocellular carcinoma via targeting KLF4. Oncotarget 8(40):68263–68269PubMedPubMedCentral Liu L, Cai X, Liu E, Tian X, Tian C (2017) MicroRNA-18a promotes proliferation and metastasis in hepatocellular carcinoma via targeting KLF4. Oncotarget 8(40):68263–68269PubMedPubMedCentral
54.
Zurück zum Zitat Wang M, Zhang J, Tong L, Ma X, Qiu X (2015) MiR-195 is a key negative regulator of hepatocellular carcinoma metastasis by targeting FGF2 and VEGFA. Int J Clin Exp Pathol 8(11):14110–14120PubMedPubMedCentral Wang M, Zhang J, Tong L, Ma X, Qiu X (2015) MiR-195 is a key negative regulator of hepatocellular carcinoma metastasis by targeting FGF2 and VEGFA. Int J Clin Exp Pathol 8(11):14110–14120PubMedPubMedCentral
55.
Zurück zum Zitat Song LY, Ma YT, Wu CF, Wang CJ, Fang WJ, Liu SK (2017) MicroRNA-195 activates hepatic stellate cells in vitro by targeting Smad7. Biomed Res Int 2017:1945631 Song LY, Ma YT, Wu CF, Wang CJ, Fang WJ, Liu SK (2017) MicroRNA-195 activates hepatic stellate cells in vitro by targeting Smad7. Biomed Res Int 2017:1945631
56.
Zurück zum Zitat Ivan M, Huang X (2014) miR-210: fine-tuning the hypoxic response. Adv Exp Med Biol 772:205–227CrossRef Ivan M, Huang X (2014) miR-210: fine-tuning the hypoxic response. Adv Exp Med Biol 772:205–227CrossRef
Metadaten
Titel
MicroRNA Expression in Focal Nodular Hyperplasia in Comparison with Cirrhosis and Hepatocellular Carcinoma
verfasst von
Gábor Lendvai
Tímea Szekerczés
Benedek Gyöngyösi
Krisztina Schlachter
Endre Kontsek
Adrián Pesti
Attila Patonai
Klára Werling
Ilona Kovalszky
Zsuzsa Schaff
András Kiss
Publikationsdatum
09.11.2018
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 3/2019
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-018-0528-z

Weitere Artikel der Ausgabe 3/2019

Pathology & Oncology Research 3/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.